SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

Court approves $305M sale of 23andMe's genetic data assets to TTAM Research Institute

A bankruptcy judge approved the sale of substantially all of 23andMe's assets, including its genetic database, to TTAM Research Institute, a nonprofit founded by co-founder Anne Wojcicki. TTAM outbid Regeneron Pharmaceuticals, which had agreed in May to pay $256 million.

NEW YORK, June 30, 2025 A U.S. bankruptcy judge approved the sale of substantially all of 23andMe's assets, including its trove of customer genetic data, to TTAM Research Institute for $305 million, the Associated Press reported.1 TTAM is a nonprofit founded by Anne Wojcicki, 23andMe's co-founder.

Terms of the deal

TTAM agreed to pay $305 million for substantially all of 23andMe's assets.1 The sale was expected to close within weeks of approval. TTAM said it would follow 23andMe's existing privacy policies and applicable law, including letting users delete their data and opt out of research, and would offer customers two years of free Experian identity theft monitoring.1

California, Kentucky, Tennessee, Texas and Utah remained opposed to the sale after approval, and California's attorney general said it did not comply with the state's genetic privacy law.1

Background

Regeneron Pharmaceuticals had agreed in May 2025 to buy most of 23andMe's assets for $256 million. TTAM won the asset in a final round of bidding held in June, according to AP.1 23andMe was in Chapter 11 bankruptcy at the time of the sale.

What it means for data sellers

The sale shows that a customer database can be the main asset in a restructuring and that bidders will compete for it. It also shows the limits: regulators objected, and the buyer had to commit to the seller's existing privacy terms. Companies holding sensitive personal data should expect any sale to be judged against what they promised users at collection. Note that the reporting cited here describes a transfer of data assets, not a license for AI training.

How the deal came together

  1. Regeneron sets the first price. In May 2025 Regeneron agreed to buy most of 23andMe's assets for $256 million.
  2. A final round of bidding. TTAM, the nonprofit founded by Wojcicki, outbid Regeneron in a final round held in June.
  3. Court approval. The bankruptcy judge approved the $305 million sale, over objections from several state attorneys general.
  4. Privacy commitments. TTAM said it would follow 23andMe's existing privacy policies, including deletion and research opt-out rights, and offer two years of identity theft monitoring.

Takeaways for companies with data

  • In a bankruptcy, customer data can be an asset that creditors and bidders compete for, and the winning price may rise well above the first offer.
  • Privacy promises made to customers shaped the buyer's conditions and drew objections from state regulators, so the terms of consent matter to value.
  • This sale was a transfer of a company's data assets, and the reporting cited here does not describe an AI-training license.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million (Associated Press via WBTV, July 2025)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.